---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042068"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:35:36.210481+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics receives Nasdaq non-compliance notice for audit committee composition

## Summary
- Notice received Oct 18, 2024, after director Matt Korenberg resigned from Board and Audit Committee effective Oct 3, 2024.
- Audit Committee now has only two independent directors (Robert Lim, Cody Price); needs three per Nasdaq Rule 5605.
- Cure period: earlier of next annual meeting or Oct 5, 2025; if meeting before Apr 1, 2025, compliance due by Apr 1, 2025.
- Company plans to appoint one independent director to Audit Committee during the cure period.
- No immediate effect on listing or trading of QLGN common stock on The Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001493152-24-042068
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315224042068/0001493152-24-042068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315224042068/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042068
- JSON: https://secwatch.observer/filing/0001493152-24-042068.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.